Denali Therapeutics Inc. (DNLI)

Market Cap	2.13B
Revenue (ttm)	n/a
Net Income (ttm)	-453.94M
Shares Out	145.28M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	613,237
Open	14.90
Previous Close	14.90
Day's Range	14.67 - 15.00
52-Week Range	10.57 - 33.33
Beta	1.33
Analysts	Strong Buy
Price Target	33.85 (+130.43%)
Earnings Date	Jul 31, 2025

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2017
• Employees: 422
• Stock Exchange: NASDAQ
• Ticker Symbol: DNLI
• Website: https://www.denalitherapeutics.com

Analyst Summary

According to 15 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price target is $33.85, which is an increase of 130.43% from the latest price.

Price Target

$33.85

(130.43% upside)

Analyst Consensus: Strong Buy